Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.
NVS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Novartis Ag with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novartis Ag ranked in the 35th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Novartis Ag, consider:
The compound growth rate in the free cash flow of Novartis Ag over the past 5.01 years is 0.03%; that's higher than only 23.37% of free cash flow generating stocks in the Healthcare sector.
NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 32.16% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
EDAP, BDX, IQV, ITGR, and GILD can be thought of as valuation peers to NVS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Bristol-Myers Squibb (NYSE:BMY) is incredibly cheap. For example, based on earnings estimates, BMY stock trades at just 7.8 times next year's earnings.Source: IgorGolovniov / Shutterstock.com In addition, it has an attractive dividend yield of 3.11%, which is likely to increase soon. I estimate the stock is worth at least $84.47, or 46% more than its present price.And that is after discounting its real worth significantly, to add in a margin of safety. The target price is primarily based on its expected earnings and dividends, its history, and comparisons with its peers.InvestorPlace - Stock Market News, Stock Advice & Trading Tips BMY Stock Earnings and Dividend ExpectationsLast quarter, the company blew away analysts' earnings forecasts. It is likely to do so again this quarte...
* Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel, September 23, 2020 – Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this patient population and recommends a pivotal confirmatory study to supplement the existing STRONG data and further support the regulatory submission for AVXS-101 IT.This guidance provides clarity on the path to registration for AVXS-101 IT. Trial design and other detai...
BERKELEY, Calif.--(BUSINESS WIRE)--Siemens Healthineers announced today a master collaboration agreement with Novartis Pharma AG to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline. The initial program assists the development of a serum NfL immunoassay to support Novartis’ MS and other neuroscience programs. NfL is a highly specific biomarker for nerve cell injury measured in cerebral spinal fluid and blood. Blood NfL levels have